Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Next Previous
Trial Profile

A Multi-Center, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
  • Focus Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma America; Tanabe Pharma America

Most Recent Events

  • 31 Oct 2025 According to Tanabe Pharma Corporation, Mitsubishi Tanabe Pharma America is now called Tanabe Pharma America
  • 13 Aug 2020 Results published in the Clinical Therapeutics
  • 26 Nov 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top